Literature DB >> 28836056

The prognostic significance of inflammation-based markers in patients with recurrent gastric cancer.

Kazuhiro Migita1, Sohei Matsumoto2, Kohei Wakatsuki2, Masahiro Ito2, Tomohiro Kunishige2, Hiroshi Nakade2, Mutsuko Kitano2, Mitsuhiro Nakatani2, Masayuki Sho2.   

Abstract

PURPOSE: The aim of this study was to evaluate the prognostic impact of inflammation-based markers, including the neutrophil-to-lymphocyte ratio (NLR) and prognostic nutritional index (PNI), in patients with recurrent gastric cancer (RGC).
METHODS: This study reviewed 167 patients with RGC. A receiver operating characteristics (ROC) curve analysis was performed to determine the NLR and PNI cutoff values. The prognostic significance of the NLR and PNI was evaluated by a multivariate analysis.
RESULTS: The optimal NLR and PNI cutoff values for predicting the 1-year survival after recurrence were 2.2 and 47, respectively. A univariate analysis revealed that the NLR (p < 0.001) and PNI (p < 0.001) were significantly associated with the survival time after recurrence, along with the histology, peritoneal recurrence, carbohydrate antigen 19-9, and chemotherapy for recurrence. In the multivariate analysis, a higher NLR (p < 0.001) and a lower PNI (p = 0.002) were independent predictors of a shorter survival time. Among the patients who underwent chemotherapy, the NLR and PNI were also independent prognostic factors.
CONCLUSIONS: Inflammation-based markers, including the NLR and PNI, are simple and useful clinical biomarkers that can be used to predict the survival time of patients with RGC.

Entities:  

Keywords:  Neutrophil-to-lymphocyte ratio; Prognostic nutritional index; Recurrent gastric cancer

Mesh:

Substances:

Year:  2017        PMID: 28836056     DOI: 10.1007/s00595-017-1582-y

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  27 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Palliative chemotherapy for advanced gastric cancer.

Authors:  S S Wöhrer; M Raderer; M Hejna
Journal:  Ann Oncol       Date:  2004-11       Impact factor: 32.976

3.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve.

Authors:  Neil J Perkins; Enrique F Schisterman
Journal:  Am J Epidemiol       Date:  2006-01-12       Impact factor: 4.897

Review 4.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Factors associated with recurrence within 2 years after curative surgery for gastric adenocarcinoma.

Authors:  Cheng-Yu Chiang; Kuo-Hung Huang; Wen-Liang Fang; Chew-Wun Wu; Jen-Hao Chen; Su-Shin Lo; Mao-Chih Hsieh; King-Han Shen; Anna Fen-Yau Li; Dau-Ming Niu; Shih-Hwa Chiou
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

6.  The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy.

Authors:  Ahmet Bilici; Tarik Salman; Bala Basak Oven Ustaalioglu; Tugba Unek; Mesut Seker; Mehmet Aliustaoglu; Cem Gezen; Tarkan Unek; Dilek Yavuzer; Mehtat Unlu; Mahmut Gumus; Ugur Yilmaz
Journal:  J Surg Res       Date:  2012-04-11       Impact factor: 2.192

7.  Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage IV gastric cancer.

Authors:  Hiroaki Tanaka; Kazuya Muguruma; Takahiro Toyokawa; Naoshi Kubo; Masaichi Ohira; Kosei Hirakawa
Journal:  Dig Surg       Date:  2014-12-03       Impact factor: 2.588

8.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

9.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

Authors:  W Chua; K A Charles; V E Baracos; S J Clarke
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

10.  Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer.

Authors:  Fanming Kong; Fangfang Gao; Jun Chen; Rongxiu Zheng; Honggen Liu; Xiaojiang Li; Peiying Yang; Geli Liu; Yingjie Jia
Journal:  Oncotarget       Date:  2016-08-23
View more
  3 in total

1.  Bioinformatic and integrated analysis identifies an lncRNA-miRNA-mRNA interaction mechanism in gastric adenocarcinoma.

Authors:  Yong Liao; Wen Cao; Kunpeng Zhang; Yang Zhou; Xin Xu; Xiaoling Zhao; Xu Yang; Jitao Wang; Shouwen Zhao; Shiyu Zhang; Longfei Yang; Dengxiang Liu; Yanpeng Tian; Weizhong Wu
Journal:  Genes Genomics       Date:  2021-03-29       Impact factor: 1.839

2.  [Prognostic Value of Neutrophil-to-lymphocyte Ratio in Patients 
with Lung Adenocarcinoma Treated with Radical Dissection].

Authors:  Gaoxiang Wang; Ran Xiong; Hanran Wu; Guangwen Xu; Caiwei Li; Xiaohui Sun; Mingran Xie
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-08-20

3.  Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification.

Authors:  Takayuki Miura; Hideo Ohtsuka; Takeshi Aoki; Shuichi Aoki; Tatsuo Hata; Tatsuyuki Takadate; Shimpei Maeda; Kyohei Ariake; Kei Kawaguchi; Kunihiro Masuda; Masaharu Ishida; Masamichi Mizuma; Kei Nakagawa; Takanori Morikawa; Fumiyoshi Fujishima; Takashi Kamei; Hironobu Sasano; Michiaki Unno
Journal:  BMC Surg       Date:  2021-03-31       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.